Dag Sehlin, PhD, is an Associate Professor of Neurobiology at Uppsala University. His research focuses on Alzheimer’s disease, developing therapeutic and diagnostic tools, including engineered antibodies targeting amyloid-beta
Dag has played an important role in the research behind the development of Lecanemab, an amyloid-beta antibody recently approved for Alzheimer's treatment by both the FDA in the U.S. and the EMA in Europe.
Episode timestamps:
00:00 - Guest Introduction: Dag Sehlin, Associate Professor of Neurobiology
03:25 - Progression of Alzheimer's Disease in the Brain
05:48 - Comorbidities and Challenges in Diagnosing Alzheimer's
12:54 - Tau and Amyloid Beta Markers in Cerebrospinal Fluid
17:00 - Future Potential of Blood Tau for Early Alzheimer's Detection
24:01 - FDA & EMA Approval of Lecanemab for Alzheimer's Treatment
25:27 - Lecanemab: First Disease-Modifying Alzheimer's Treatment
35:23 - Clinical Benefits of Lecanemab Beyond Cognitive Function (Quality of Life, Hospitalization Rates and More)
58:39 - Dose-Dependent Side Effects and Future Improvements
01:00:54 - Transferrin Receptor "Trojan Horse" Mechanism for Blood-Brain Barrier Penetration
01:15:16 - Neuroinflammation: Beneficial vs. Harmful Effects and Possible Solutions
01:39:37 - AI and Brain Imaging: Enhancing Precision
01:42:04 - Enhancing Collaboration Between Academia and Big Pharma Companies
